Sunesis Pharmaceuticals (SNSS) Sets New 12-Month Low at $1.71

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)’s share price reached a new 52-week low on Friday . The stock traded as low as $1.71 and last traded at $1.77, with a volume of 152467 shares. The stock had previously closed at $1.84.

Separately, Zacks Investment Research cut shares of Sunesis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $4.00.

The firm has a market cap of $70.83 million, a P/E ratio of -1.30 and a beta of 1.84.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. On average, research analysts forecast that Sunesis Pharmaceuticals, Inc. will post -0.89 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Sunesis Pharmaceuticals stock. Wells Fargo & Company MN grew its stake in shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) by 38.4% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 64,367 shares of the biopharmaceutical company’s stock after acquiring an additional 17,853 shares during the period. Wells Fargo & Company MN owned 0.19% of Sunesis Pharmaceuticals worth $175,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 43.80% of the company’s stock.

Sunesis Pharmaceuticals Company Profile (NASDAQ:SNSS)

Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

Featured Article: Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply